Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imerys's change in receivables for the quarter that ended in Dec. 2025 was $86 Mil. It means Imerys's Accounts Receivable
declined by $86 Mil
from Jun. 2025 to Dec. 2025 .
Imerys's change in receivables for the fiscal year that ended in Dec. 2025 was $14 Mil. It means Imerys's Accounts Receivable
declined by $14 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Imerys's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 37.54.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Imerys's liquidation value for the
six
months ended in Dec. 2025 was $-2,455 Mil.
Imerys (OTCPK:IMYSF) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Imerys's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imerys Change In Receivables Related Terms
Imerys Change In Receivables Historical Data
* Premium members only.
The historical data trend for Imerys's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of $15 Mil mean?
Imerys (IMYSF) has a Change In Receivables of $15 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Imerys and its competitors.
Is Imerys' Change In Receivables too high?
Imerys' current Change In Receivables is $15 Mil. Overall, Imerys has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imerys' Change In Receivables compare to LIN and SHW?
Imerys' Change In Receivables of $15 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Chemicals company?
A good Change In Receivables depends on the Chemicals industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Imerys and its competitors. Imerys's current Change In Receivables is $15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imerys stock overvalued right now?
Based on GuruFocus' analysis, Imerys (IMYSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $31.79, compared to a current price of $24.72 — trading 22.3% below its estimated fair value. The current Change In Receivables is $15 Mil. Imerys' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Imerys (IMYSF), the current Change In Receivables is $15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imerys (IMYSF) Overvalued in 2026?
Based on GuruFocus' analysis, Imerys stock appears to be undervalued.
The current stock price of $24.72 is trading 22.3% below its estimated GF Value™ of $31.79.
GuruFocus considers Imerys to be Modestly Undervalued.
Key valuation signals for IMYSF:
Change In Receivables: $15 Mil
GF Value™: $31.79 vs. price of $24.72 (22.3% below fair value)
No single metric tells the full story. See the IMYSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imerys manufactures and sells mineral-based specialty applications for multiple industries, including construction, renovation, iron and steel, and automotive. The company is organized into three activities: Performance Minerals comprises three geographic business areas - Europe, the Middle East and Africa, the Americas, and the Asia Pacific. It mainly serves the plastics, rubber, paints & coatings, filtration, renewable energy, and paper & board markets. The company operates in three segments: Performance Minerals, Refractory, Abrasives & Construction, and Solutions for Energy Transition. The majority of the revenue is generated from the Performance Minerals segment.
59GF Score
Get the complete analysis for IMYSF
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMYSF has been successfully added to your 
